Search Results - "McLachlan, Donald R. C."

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    Aluminum in Neurological and Neurodegenerative Disease by McLachlan, Donald R C, Bergeron, Catherine, Alexandrov, Peter N, Walsh, William J, Pogue, Aileen I, Percy, Maire E, Kruck, Theodore P A, Fang, Zhide, Sharfman, Nathan M, Jaber, Vivian, Zhao, Yuhai, Li, Wenhong, Lukiw, Walter J

    Published in Molecular neurobiology (01-02-2019)
    “…With continuing cooperation from 18 domestic and international brain banks over the last 36 years, we have analyzed the aluminum content of the temporal lobe…”
    Get full text
    Journal Article
  2. 2

    Retraction Note: Aluminum in Neurological and Neurodegenerative Disease by McLachlan, Donald R. C., Bergeron, Catherine, Alexandrov, Peter N., Walsh, William J., Pogue, Aileen I., Percy, Maire E., Kruck, Theodore P. A., Fang, Zhide, Sharfman, Nathan M., Jaber, Vivian, Zhao, Yuhai, Li, Wenhong, Lukiw, Walter J.

    Published in Molecular neurobiology (01-03-2020)
    “…The Editor-in Chief of Molecular Neurobiology has retracted this article [1] at the request of the corresponding author. This is because it significantly…”
    Get full text
    Journal Article
  3. 3

    Run-on gene transcription in human neocortical nuclei. Inhibition by nanomolar aluminum and implications for neurodegenerative disease by Lukiw, W J, LeBlanc, H J, Carver, L A, McLachlan, D R, Bazan, N G

    Published in Journal of molecular neuroscience (01-08-1998)
    “…The incorporation of [alpha-32P]-uridine triphosphate into DNA transcription products was examined in short post-mortem interval (PMI) human brain neocortical…”
    Get full text
    Journal Article
  4. 4

    RETRACTED ARTICLE: Aluminum in Neurological and Neurodegenerative Disease by McLachlan, Donald R. C., Bergeron, Catherine, Alexandrov, Peter N., Walsh, William J., Pogue, Aileen I., Percy, Maire E., Kruck, Theodore P. A., Fang, Zhide, Sharfman, Nathan M., Jaber, Vivian, Zhao, Yuhai, Li, Wenhong, Lukiw, Walter J.

    Published in Molecular neurobiology (01-02-2019)
    “…With continuing cooperation from 18 domestic and international brain banks over the last 36 years, we have analyzed the aluminum content of the temporal lobe…”
    Get full text
    Journal Article
  5. 5

    Localization of a new ferritin heavy chain sequence present in human brain mRNA to chromosome 11 by Percy, M E, Bauer, S J, Rainey, S, McLachlan, D R, Dhar, M S, Joshi, J G

    Published in Genome (01-06-1995)
    “…Two types of ferritin heavy (H) chain clones have been isolated from cDNA libraries of human fetal and adult brain: one corresponds to the ferritin H chain…”
    Get more information
    Journal Article
  6. 6

    Age-associated chromosome 21 loss in Down syndrome: possible relevance to mosaicism and Alzheimer disease by Percy, M E, Markovic, V D, Dalton, A J, McLachlan, D R, Berg, J M, Rusk, A C, Somerville, M J, Chodakowski, B, Andrews, D F

    Published in American journal of medical genetics (01-03-1993)
    “…We previously observed low level mosaicism (2-4% normal cells) in phytohemagglutinin-stimulated peripheral blood lymphocytes (PBL) in 29% of a small group of…”
    Get more information
    Journal Article
  7. 7

    Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered? by Savory, J, Exley, C, Forbes, W F, Huang, Y, Joshi, J G, Kruck, T, McLachlan, D R, Wakayama, I

    “…Aluminum (Al) is unquestionably neurotoxic in both experimental animals and certain human diseases. Minute quantities injected intracerebrally into rabbits…”
    Get more information
    Journal Article
  8. 8

    A predictor for side effects in patients with Alzheimer's disease treated with deferoxamine mesylate by Kruck, T P, Fisher, E A, McLachlan, D R

    Published in Clinical pharmacology and therapeutics (01-01-1993)
    “…In a previously reported clinical trial, patients with Alzheimer's disease were treated with deferoxamine mesylate, which resulted in a 50% reduction in the…”
    Get more information
    Journal Article
  9. 9

    Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelation by Kruck, T P, Fisher, E A, McLachlan, D R

    Published in Clinical pharmacology and therapeutics (01-10-1990)
    “…Deferoxamine treatment may produce serious side effects that can be eliminated by modification of treatment and by control of deferoxamine metabolism. A…”
    Get more information
    Journal Article
  10. 10
  11. 11